Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lineage Cell Therapeutics Inc
(NY:
LCTX
)
0.8602
-0.0474 (-5.22%)
Official Closing Price
Updated: 8:00 PM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Lineage Cell Therapeutics Inc
< Previous
1
2
3
Next >
LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
LCTX Stock Earnings: Lineage Cell Therapeutics Meets EPS, Beats Revenue for Q1 2024
May 09, 2024
LCTX stock results show that Lineage Cell Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023
March 07, 2024
LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Lineage Cell Therapeutics: Q4 Earnings Insights
March 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
February 01, 2024
Via
Benzinga
Lineage Cell Therapeutics: Q3 Earnings Insights
November 09, 2023
Via
Benzinga
Earnings Preview: Lineage Cell Therapeutics
November 08, 2023
Via
Benzinga
Lineage Cell Therapeutics Earnings Preview
August 09, 2023
Via
Benzinga
Earnings Scheduled For March 7, 2024
March 07, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
Via
Benzinga
A Preview Of Lineage Cell Therapeutics's Earnings
March 06, 2024
Via
Benzinga
Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying
January 03, 2024
The Dow Jones index closed higher by around 25 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 29, 2023
Via
Benzinga
3 Penny Stocks to Buy for the Next Bull Run
November 11, 2023
While penny stocks to buy represent a terribly risky venture, it’s possible that maybe one of these ideas could skyrocket.
Via
InvestorPlace
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks
October 17, 2023
Here are the best longevity stocks to consider. Each stock listed comes with their unique reasons to buy them.
Via
InvestorPlace
EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics
September 06, 2023
Lineage Cell Therapeutics Inc (NYSE: LCTX) has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and...
Via
Benzinga
Lineage Cell Therapeutics: Q1 Earnings Insights
May 11, 2023
Via
Benzinga
Lineage Cell Therapeutics's Return On Capital Employed Overview
March 14, 2023
Via
Benzinga
Preview: Lineage Cell Therapeutics's Earnings
March 08, 2023
Via
Benzinga
Why DLocal Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
August 16, 2023
Gainers
Via
Benzinga
Lineage Cell Therapeutics' Lung Cancer Vaccine: Initial Data Reveals Modest, Durable Immune Response
July 24, 2023
Lineage Cell Therapeutics Inc (NYSE: LCTX) and Cancer Research UK revealed primary and secondary endpoint results from the recently completed clinical study of VAC2 in advanced non-small
Via
Benzinga
Harley-Davidson, Sportsman's Warehouse And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
April 13, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
3 Penny Stocks to Buy During Market Downturns
April 10, 2023
If you're looking for penny stocks to buy that can weather economic turmoil, these should make the cut due to their strong fundamentals.
Via
InvestorPlace
Earnings Scheduled For August 10, 2023
August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
Via
Benzinga
EXCLUSIVE: Lineage Cell Inks Exclusive Agreement For Novel Cell-Based Therapies With Potential In Neurology
February 22, 2023
Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive option and license agreement with Eterna Therapeutics Inc for beta 2 microglobulin (B2M)-deficient induced pluripotent stem cell...
Via
Benzinga
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
January 25, 2023
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development.
Via
Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
January 06, 2023
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.
Via
Investor's Business Daily
Earnings Preview: Lineage Cell Therapeutics
November 09, 2022
Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-11-10. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
November 02, 2022
Upgrades
Via
Benzinga
121 Stocks That Hit Their 52-Week Low
October 14, 2022
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows.
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.